Guardian Pharmacy Services (GRDN) Expected to Announce Earnings on Thursday

Key Points

• Guardian Pharmacy Services is expected to report Q3 2026 results after market close on November 5, with analysts forecasting $0.3146 in EPS and $365.76 million in revenue.
• The company exceeded expectations in its previous quarter, reporting $0.29 EPS and $351.77 million in revenue versus estimates of $0.26 and $340.45 million, respectively.
• Analyst sentiment remains favorable, with nine Buy ratings and one Hold rating, a “Moderate Buy” consensus, and an average price target of $45.57 versus the stock’s recent $40.38 price.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Guardian Pharmacy Services to post earnings of $0.3146 per share and revenue of $365.76 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.03. The business had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. On average, analysts expect Guardian Pharmacy Services to post $1.18 EPS for the current fiscal year and $1.33 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

Shares of NYSE GRDN opened at $40.38 on Thursday. Guardian Pharmacy Services has a 1 year low of $26.34 and a 1 year high of $48.33. The company's 50-day moving average is $40.96 and its 200 day moving average is $37.91. The stock has a market capitalization of $2.01 billion, a P/E ratio of 39.20, a P/E/G ratio of 2.06 and a beta of 0.03.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Oppenheimer increased their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Weiss Ratings cut shares of Guardian Pharmacy Services from a "buy (b)" rating to a "buy (b-)" rating in a research note on Friday, October 23rd. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Sunday. KeyCorp assumed coverage on Guardian Pharmacy Services in a research report on Tuesday, September 22nd. They set an "overweight" rating and a $52.00 price objective on the stock. Finally, Truist Financial boosted their price objective on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a "buy" rating in a report on Monday, September 21st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $45.57.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company's services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents' medication regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.